List of Studies ( Metabolite:11-HDoHE)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST002470 | AN004032 | Linking bacterial metabolites to disease-associated microbes to uncover mechanisms of host-microbial interactions in intestinal inflammation. Human plasma profiling | Blood | Human | Ulcerative colitis | Broad Institute of MIT and Harvard | Abundance |
ST002471 | AN004036 | Linking bacterial metabolites to disease-associated microbes to uncover mechanisms of host-microbial interactions in intestinal inflammation. Human stool profiling | Feces | Human | Ulcerative colitis | Broad Institute of MIT and Harvard | Abundance |
ST002247 | AN003673 | Microbiota and Health Study (Dhaka, Bangladesh) | Feces | Human | Broad Institute of MIT and Harvard | Abundances | |
ST002455 | AN004005 | Organism-Wide Analysis of Sepsis Reveals Mechanisms of Systemic Inflammation | Blood | Mouse | Sepsis | University of Chicago | intensity |
ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | ng/g tissue |
ST002354 | AN003843 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | ng/g tissue |
ST001951 | AN003176 | Quantification of ω-3 fatty acids and their derivatives in lungs from hypoxia-induced pulmonary hypertension (PH) mice. | Lung | Mouse | Pulmonary hypertension | University of Tokyo | ng/mg tissue |
ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Blood | Rat | Cancer | UConn Health | ng/mL |
ST002354 | AN003845 | Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes. | Colon | Rat | Cancer | UConn Health | ng/mL |
ST000004 | AN000004 | Lipidomics studies on NIDDK / NIST human plasma samples | Blood | Human | LIPID MAPS | nM | |
ST000916 | AN001491 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | nM |
ST003049 | AN005000 | Plasma instead of serum avoids critical confounding of clinical metabolomics studies by platelets | Blood | Human | University of Vienna | normalized AUC | |
ST001206 | AN002008 | Effects of cold exposure on serum lipidomic in mice | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001207 | AN002009 | Lipidomics in the serum of cold exposed mice treated with 12-LOX inhibitor LOXBlock-1 | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001213 | AN002024 | Serum lipidomic profile of cold-exposed Ucp1cre/12-LOX KO mice | Blood | Mouse | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001214 | AN002025 | Lipidommics in the serum of human subjects | Blood | Human | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST001215 | AN002026 | Effect of Mirabegron Treatment on serum lipidome | Blood | Human | Joslin Diabetes Center - Harvard Medical School | Peak area | |
ST000915 | AN001485 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | pmol/mg |
ST002246 | AN003669 | Longitudinal fecal metabolomic profiles from mothers and their infants in the EDIA study | Feces | Human | Broad Institute of MIT and Harvard | Unitless Abundances |